Skip to main content
logo
Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
36.36
-0.26 (-0.71%)
At close: Sep 4, 2026, 4:00 PM EDT
37.19
+0.83 (2.28%)
After-hours: Sep 4, 2026, 7:59 PM EDT

Teva Pharmaceutical Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
7061,410-1,639-559-2,446417
Depreciation & Amortization
9881,0021,0591,1531,3081,330
Loss (Gain) From Sale of Assets
-20--22-4110-
Asset Writedown & Restructuring Costs
1,6971,0282,5551,0782,447594
Loss (Gain) From Sale of Investments
-----104
Stock-Based Compensation
168157123121124119
Other Operating Activities
-530-582-394-312-1,208-65
Change in Accounts Receivable
-7-17324512334-574
Change in Inventory
181152166-147-163380
Change in Accounts Payable
-123-152581,5882,012764
Change in Other Net Operating Assets
-1,162-1,330-1,104-1,525-828-2,271
Operating Cash Flow
1,8981,6491,2471,3681,590798
Operating Cash Flow Growth
36.55%32.24%-8.85%-13.96%99.25%-34.38%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-551-501-498-526-548-562
Cash Acquisitions
-696--15--7-
Divestitures
5434436868311
Investment in Securities
11-15-31-463125
Other Investing Activities
-252-5-1
Investing Cash Flow
377377929686561,523

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
---700-700
Long-Term Debt Issued
-2,298-2,451-4,974
Total Debt Issued
-72,298-3,151-5,674
Short-Term Debt Repaid
----700--700
Long-Term Debt Repaid
--4,112-1,641-4,152-1,369-7,140
Total Debt Repaid
-467-4,112-1,641-4,852-1,369-7,840
Net Debt Issued (Repaid)
-474-1,814-1,641-1,701-1,369-2,166
Other Financing Activities
73-337-150-212-118-6
Financing Cash Flow
-401-2,151-1,791-1,913-1,487-2,172

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-4121-174-30-123-128
Net Cash Flow
1,4942567439363621

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
1,3471,1487498421,042236
Free Cash Flow Growth
51.35%53.27%-11.04%-19.19%341.52%-63.01%
Free Cash Flow Margin
7.78%6.65%4.53%5.31%6.98%1.49%
Free Cash Flow Per Share
1.160.990.660.750.940.21
Levered Free Cash Flow
2,2202,0322,6233,2982,9002,307
Unlevered Free Cash Flow
2,7582,6043,2493,9413,4812,863

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
9509501,0041,078948913
Cash Income Tax Paid
558558471298543495
Change in Working Capital
-1,111-1,366-435-721,355-1,701
SEC Filings: 10-K · 10-Q